1. Introduction {#s0005}
===============

One of the major challenges facing transplant candidates is the clinical complications that can occur after organ transplantation ([@bb0105]). Intestinal infections may occur after transplantation, leading to important clinical manifestations such as diarrhea or dysentery, increasing the morbidity and mortality rates in this population ([@bb0015]; [@bb0105]).

*Blastocystis* sp. is an intestinal protozoan found in fecal samples from many animal species, including humans ([@bb0130]). This organism is present worldwide, with a prevalence ranging from 30% to 60% in developing countries ([@bb0135]). In Brazil, its occurrence ranges from 1.4% to 57.8% ([@bb0020]; [@bb0025]). Some studies have associated the presence of *Blastocystis* sp. with non-specific gastrointestinal symptoms such as nausea, abdominal pain, and chronic diarrhea, which may be severe in immunocompromised patients ([@bb0150]; [@bb0055]; [@bb0105]; [@bb0035]). In recent studies, the occurrence of *Blastocystis* sp. has been found to be high in fecal samples of immunocompromised patients ([@bb0150]; [@bb0110]).

Several studies have evaluated the occurrence of *Blastocystis* sp. subtypes in fecal isolates ([@bb0065]; [@bb0100]; [@bb0060]), but to date there are no reports on the subtypes found in transplant candidates. Thus, the aim of this study was to evaluate the occurrence and molecular identification of *Blastocystis* sp. subtypes in fecal samples from transplant candidates.

2. Materials and methods {#s0010}
========================

2.1. Study population {#s0015}
---------------------

This retrospective study was conducted on stool specimens from transplant candidates and was approved by the Research Ethics Committee of Hospital das Clínicas of Faculdade de Medicina, Universidade de São Paulo, São Paulo State (HC/FMUSP) from 2011 to 2013 (protocol no. 0123/10). A total of 150 fecal samples from transplant candidates were analyzed: 51 renal transplant candidates (RT), 48 hepatic transplant candidates (HT), and 51 bone marrow transplant candidates (BMT). Of the 150 patients, 56 (37.3%) were females and 94 (62.7%) were males aged from 19 to 83 years. The indications for the transplants were diabetic nephropathy, chronic renal failure, lupus nephritis, and post-sepsis nephropathy for RT; cirrhosis due to hepatitis B and C virus, alcoholic, or cryptogenic, non-alcoholic steatosis, and autoimmune hepatitis for HT; multiple myeloma, acute myeloid leukemia, non-Hodgkin lymphoma, Hodgkin disease, severe aplastic anemia, and myelofibrosis for BMT. Many of these underlying diseases do confer some degree of immune dysfunction.

At the time of collection, the fecal samples were analyzed by spontaneous sedimentation, modified Baermann, and agar plate culture techniques ([@bb0040]). The remainder of the fecal samples were divided into aliquots and stored at −20 °C for subsequent molecular analysis.

2.2. Molecular analysis {#s0020}
-----------------------

Approximately 200 mg of fecal sample was used for extraction of DNA with a QIAamp DNA Stool Mini Kit (QIAGEN, Hilden, Germany), following the manufacturer\'s instructions. The DNA extracted was amplified by conventional polymerase chain reaction (PCR), using specific primers: BhRDr (R: 5′-GAG CTT TTA ACT GCA ACA ACG-3′) and RD5 (F: 5′-ATC TGG TTG ATC CTG CCA GT-3′) located in *SSU*-rDNA of *Blastocystis* sp. that amplify a fragment of \~600 bp ([@bb0120]). The amplification reaction conditions were as described by [@bb0065] in a final volume of 10 μL containing ∼50 ng μL^−1^ DNA, 2.0 μg of BSA, 0.2 mM each dNTP, 1.5 mM MgCl~2~, 2 pM each primer (forward and reverse), 1× PCR buffer, and 1.25 U of GoTaq DNA polymerase (Promega Corporation, Madison, WI, USA). PCR amplification was conducted using a Master cycler Ep gradient S thermocycler (Eppendorf, Hamburg, Germany) and the following conditions: initial denaturation step at 94 °C for 2 min; 30 cycles at 94 °C (denaturation) for 1 min, 61 °C (annealing) for 1 min, and 72 °C for 1 min (extension); and a final extension step of 72 °C for 2 min. Negative (PCR mix with water) and positive (PCR mix with *Blastocystis* sp. culture samples) controls were included in all molecular analysis. Controls for the DNA extraction were the following universal primers: 18SEUDIR (F: 5′-TCT GCC CTA TCA ACT TTC GAT GG-3′) and 18SEUINV (R: 5′-TAA TTT GCG CGC CTG CTG-3′) located in the eukaryotic *SSU*-rDNA region ([@bb0145]).

PCR-positive products were initially purified by the enzyme ExoSAP (GE Healthcare, Piscataway, NJ, USA), and then sequenced by the Sanger method ([@bb0115]). The sequences were evaluated for quality and to determine the subtype (ST) and allele (a) of each sample; the sequences were aligned with other *Blastocystis* sequences present in GenBank using the BLAST tool and the *Blastocystis* Multilocus Sequence Typing online database. The sequences were submitted to GenBank under number: MN658570-MN658583, MN718159, MN686280-MN686283 and MN658567-MN658569.

3. Results {#s0025}
==========

The analysis of the parasitology showed that 12.7% (19 of 150) patients were positive, 11 RT patients (9 for *Strongyloides stercoralis* and 2 for *Entamoeba coli*), 4 HT patients (3 for *S. stercoralis* and 1 for *Endolimax nana*), and 4 BMT patients (2 for *S. stercoralis* and 2 for *E. coli*).

Amplification of *Blastocystis* DNA was observed in 16% (24 of 150) of samples, 31.4% (16 of 51) from RT patients, 10.4% (5 of 48) from HT patients, and 5.9% (3 of 51) from BMT patients. After sequences analysis against the databases, all 24 sequences showed good quality and confirmed *Blastocystis* sp. DNA, with identity ranging from 87% to 100%.

Of the samples confirmed by sequencing as *Blastocystis* sp., the following subtypes were identified: ST1 in 9 (37.5%) samples, ST2 in 3 samples (12.5%), ST3 in 11 samples (45.8%), and ST7 in 1 sample (4.2%). The following subtypes were identified in RT candidates: ST1 (n = 8), ST2 (n = 1), ST3 (n = 6), and ST7 (n = 1). For HT candidates, the subtypes identified were ST2 (n = 2) and ST3 (n = 3); and for BMT candidates, the subtypes were ST1 (n = 1) and ST3 (n = 2) ([Table 1](#t0005){ref-type="table"}).Table 1Distribution of subtypes of *Blastocystis* sp. (ST) in fecal samples of transplant candidates from the HC/FMUSP.Table 1Transplant candidatesRT (n = 51)HT (n = 48)BMT (n = 51)No.%No.%No.%ST1850.0----133.3ST216.25240.0----ST3637.5360.0266.7ST716.25--------Total16100.05100.03100.0[^1]

MLST analysis of the sequences showed alleles 4 (8 of 9) and 78/81 (1 of 9) among ST1; alleles 11 (1 of 3) and 12 (2 of 3) among ST2; alleles 34 (4 of 11), 36 (4 of 11), 37 (2 of 11) and 54 (1 of 11) among ST3; and allele 96 in ST7 isolate ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Frequency of *Blastocystis* spp. subtypes/alleles in transplant candidates from the HC/FMUSP.Fig. 1

4. Discussion {#s0030}
=============

Epidemiological studies show that the occurrence of *Blastocystis* sp., a gastrointestinal protozoan, is high ([@bb0085]; [@bb0015]; [@bb0055]). In Brazil, molecular studies have reported positivity ranging from 40.7% to 71% ([@bb0080]; [@bb0030]). However, this is the first study to investigate the occurrence and molecular characterization of *Blastocystis* sp. in transplant candidates. Our results showed a positivity of 16%, which is lower than that in other studies in Brazil ([@bb0080]; [@bb0030]).

There is a lack of reports about *Blastocystis* sp. in the study population. Considering chronic renal failure as a possible indication for RT, parasitology studies in Brazil showed a positivity of 20.1% ([@bb0055]) and 24.5% ([@bb0045]) for *Blastocystis* sp. In addition, [@bb0075] reported 4.7% positivity for *Blastocystis* sp. in RT patients. [@bb0105] described these protozoa as an important agent responsible for diarrhea in this group. In the present study, we observed positivity of 31.4% for *Blastocystis* sp. in RT patients by molecular analysis. Different results were demonstrated recently by [@bb0150] who reported occurrence of 4.4% for *Blastocystis* sp. in hemodialysis patients using molecular analysis.

To date, there have been no previous studies investigating colonization by *Blastocystis* sp. in transplant candidates, especially HT and BMT candidates; it was therefore not possible to compare our findings with any other studies. The present study showed *Blastocystis* sp. DNA in 10.4% and 5.9% of the samples from HT and BMT candidates, respectively. A previous analysis of samples from patients with hematologic malignancies demonstrated that 16% were positive for *Blastocystis* sp., which was less than for BMT patients ([@bb0090]). One possible explanation for the variation in positivity may be the molecular technique used; in the present study, we used conventional PCR, whereas [@bb0090] used real-time PCR. In addition, the different epidemiologic conditions in the region where the samples were obtained may explain the differences in positivity for *Blastocystis* sp.

In this study, the subtypes identified were ST3 (45.8%), ST1 (37.5%), ST2 (12.5%), and ST7 (4.2%), similar to the reports in the literature ([@bb0100]; [@bb0060]). According to [@bb0010], most human isolates correspond to ST3, followed by ST1, ST2, and ST4. However, ST4 was not isolated in the present study, which can be explained by the geographic distribution of this subtype. It has been proposed that only 2% of isolates in South America correspond to ST4 ([@bb0100]). ST1--3 have been reported to have the highest occurrence in several countries ([@bb0050]; [@bb0010]; [@bb0070]) and in Brazil ([@bb0125]; [@bb0065]; [@bb0030]).ST5--9 are rarely found in humans; ST6 and ST7 are commonly detected in birds ([@bb0050]; [@bb0100]; [@bb0010]). On other hand, Brazilian studies conducted in the state of São Paulo detected ST6 in human samples ([@bb0065]; [@bb0030]). In the current study, ST6 was not observed, but ST7 was isolated in 4.2%, similar to the findings reported recently ([@bb0080]). [@bb0070] found ST7 and ST8 in 2.9% of human isolates in Italy. Of note all isolates had single ST infections and none evidence of mixed infections was found.

The genetic diversity of *Blastocystis* sp. may be related to the possible pathogenic potential of this organism ([@bb0130]). In the current study, ST1, ST2, ST3, and ST7 were observed in RT candidates, ST2 and ST3 in HT candidates, and ST1 and ST3 in BMT candidates. ST3 was found in all 3 groups, whereas ST1 was not detected in HT candidates, and ST2 was not isolated from BMT candidates. No relationship was found between the subtypes and the indications for the transplant. In the present study, only 2 subtypes, ST1 and ST3, were found in BMT candidates, which may be due to the low occurrence of *Blastocystis* sp. in this group.

Different regions of *Blastocystis* DNA have recently been proposed for subtype differentiation, such as rDNA internal spacers ([@bb0140]), mitochondrial markers ([@bb0095]), or the pyruvate ferredoxin oxidoreductase gene ([@bb0005]). However, analysis of the multilocus gene sequences (MLST) has been shown to be an important tool for distinguishing taxa, especially from problematic and enigmatic species such as *Blastocystis* sp. ([@bb0100]).

In our findings, alleles 34, 36, and 37 were identified within ST3, reinforcing the greater genetic variability within this subtype. Although there are few MLST studies, some authors point to the importance of sequence analysis methods to improve the understanding of the possible pathogenicity of *Blastocystis* sp. subtypes/alleles ([@bb0130]).

The present study has limitations; the main one is related to the techniques used for parasitologic diagnosis, which may make it impossible to detect *Blastocystis* forms in fecal samples and, consequently, give negative parasitologic results. In addition, the study was retrospective; when the samples were collected, the main objective was to search for *S. stercoralis* larvae. Moreover, knowing the difficulty of identifying *Blastocystis* forms, positivity is operator dependent. This may explain the absence of positive parasitology for *Blastocystis*. Thus, this study focused on identifying *Blastocystis* using only molecular tools rather than parasitology techniques.

5. Conclusion {#s0035}
=============

This is the first study on molecular identification of *Blastocystis* sp. in transplant candidates. Our molecular analysis describes a higher occurrence of ST3, followed by ST1, ST2, and ST7, in fecal samples of transplant candidates, and reinforces the importance of new studies to investigate *Blastocystis* sp. among this population.
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